Combining cytokine-based immunotherapy AM0010 with Pembrolizumab
A combination of the immunotherapies AM0010 and the immune checkpoint inhibitor pembrolizumab was well tolerated and resulted in durable objective tumor responses in some patients with renal cell carcinoma (RCC) and non-small ...
Sep 27, 2016
0
3